Evogene Ltd. (EVGN)
- Previous Close
0.6800 - Open
0.6800 - Bid 0.6798 x 100
- Ask 0.7096 x 100
- Day's Range
0.6800 - 0.7500 - 52 Week Range
0.4500 - 1.4400 - Volume
47,373 - Avg. Volume
86,609 - Market Cap (intraday)
35.203M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4500 - Earnings Date Aug 15, 2024 - Aug 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.42
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
www.evogene.comRecent News: EVGN
Performance Overview: EVGN
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVGN
Valuation Measures
Market Cap
34.46M
Enterprise Value
19.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.63
Price/Book (mrq)
4.25
Enterprise Value/Revenue
2.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-233.66%
Return on Assets (ttm)
-30.90%
Return on Equity (ttm)
-84.70%
Revenue (ttm)
9.19M
Net Income Avi to Common (ttm)
-21.47M
Diluted EPS (ttm)
-0.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
26.61M
Total Debt/Equity (mrq)
3.94%
Levered Free Cash Flow (ttm)
-11.75M